Oligomeric compounds for the modulation of survivin expression

Details for Australian Patent Application No. 2004209598 (hide)

Owner Enzon Pharmaceuticals, Inc. Santaris Pharma A/S

Inventors Petersen, Kamille Dumong; Hansen, Bo; Wissenbach, Margit; Westergaard, Majken; Thrue, Charlotte Albaek

Agent Cullen & Co

Pub. Number AU-B-2004209598

PCT Pub. Number WO2004/069991

Priority PA 2003 01708 18.11.03 DK; PA 2003 00183 10.02.03 DK

Filing date 10 February 2004

Wipo publication date 19 August 2004

Acceptance publication date 6 August 2009

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

18 August 2005 PCT application entered the National Phase

  PCT publication WO2004/069991 Priority application(s): WO2004/069991

1 November 2007 Assignment before Grant

  Santaris Pharma A/S The application has been assigned to Santaris Pharma A/S; Enzon Pharmaceuticals, Inc.

6 August 2009 Application Accepted

  Published as AU-B-2004209598

3 December 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004209599-Oligomeric compounds for the modulation of ras expression

2004209597-Oligomeric compounds for the modulation of thioredoxin expression